{
    "id": 531,
    "fullName": "MPL W515K",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "MPL W515K lies within the cytoplasmic domain of the Mpl protein (UniProt.org). W515K results in activation of Mpl signaling as indicated by constitutive activation of Jak/Stat, Ras/Mapk, and Pi3k signaling (PMID: 26450985), is transforming in cell culture (PMID: 18528423, PMID: 26437785), and induces tumor formation in mice (PMID: 18528423).",
            "references": [
                {
                    "id": 12365,
                    "pubMedId": 26450985,
                    "title": "Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26450985"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 9810,
                    "pubMedId": 18528423,
                    "title": "New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18528423"
                },
                {
                    "id": 5154,
                    "pubMedId": 26437785,
                    "title": "Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26437785"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4352,
        "geneSymbol": "MPL",
        "terms": [
            "MPL",
            "C-MPL",
            "CD110",
            "MPLV",
            "THCYT2",
            "THPOR",
            "TPOR"
        ]
    },
    "variant": "W515K",
    "createDate": "05/13/2014",
    "updateDate": "09/29/2018",
    "referenceTranscriptCoordinates": {
        "id": 100294,
        "transcript": "NM_005373",
        "gDna": "chr1:g.43349337_43349338delTGinsAA",
        "cDna": "c.1543_1544delTGinsAA",
        "protein": "p.W515K",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 13700,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "MPL W515K is associated with intermediate prognosis and higher risk of thrombosis when compared to the presence of CALR mutations in patients with primary myelofibrosis (NCCN.org).",
            "molecularProfile": {
                "id": 590,
                "profileName": "MPL W515K"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1100,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a phase II study of patients with myelofibrosis, 2/2 patients with MPL W515L/K had tumor response to everolimus, with one patient displaying clinical benefit (PMID: 21725052).",
            "molecularProfile": {
                "id": 590,
                "profileName": "MPL W515K"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 838,
                    "pubMedId": 21725052,
                    "title": "Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21725052"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 590,
            "profileName": "MPL W515K",
            "profileTreatmentApproaches": [
                {
                    "id": 8710,
                    "name": "JAK Inhibitor (Pan) - ATP competitive",
                    "profileName": "MPL W515K"
                },
                {
                    "id": 8713,
                    "name": "JAK2 Inhibitor",
                    "profileName": "MPL W515K"
                },
                {
                    "id": 8711,
                    "name": "JAK Inhibitor (Pan)",
                    "profileName": "MPL W515K"
                },
                {
                    "id": 8712,
                    "name": "JAK2 Inhibitor - ATP competitive",
                    "profileName": "MPL W515K"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 100294,
            "transcript": "NM_005373",
            "gDna": "chr1:g.43349337_43349338delTGinsAA",
            "cDna": "c.1543_1544delTGinsAA",
            "protein": "p.W515K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}